Delving into the Latest Updates on The Catholic University of Korea with Synapse

概览

疾病领域	数量

肿瘤	7
血液及淋巴系统疾病	1
神经系统疾病	1

排名前五的药物类型	数量

单克隆抗体	3
小分子化药	3
合成多肽	2
间充质干细胞疗法	1
miRNA	1

排名前五的靶点	数量

LGR5(富含亮氨酸重复序列的G蛋白偶联受体-5)	1
SDF-1(C-X-C基序趋化因子配体12)	1
DDX53	1
microRNA let-7i-5p	1
VEGFR3(血管内皮细胞生长因子受体3)	1

关联

15

项与 The Catholic University of Korea 相关的药物

Oleanolic Acid

齐墩果酸

靶点

Nrf2

作用机制

Nrf2刺激剂

在研机构

The Catholic University of Korea

原研机构-

在研适应症

肝炎 [+1]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期1983-01-01

LB-217

靶点

DDX53

作用机制

DDX53抑制剂

在研机构

Daewon Pharmaceutical Co., Ltd. [+2]

原研机构

L-Base Co., Ltd. [+2]

在研适应症

结直肠癌 [+1]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

peptide 4(CHA University)

靶点

VEGFR3

作用机制

VEGFR3拮抗剂

在研机构

The Catholic University of Korea [+1]

原研机构

CHA University [+1]

在研适应症

急性髓性白血病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

2

项与 The Catholic University of Korea 相关的临床试验

NCT02370017 / Unknown status临床2期IIT

Combined Effect of Autologous Ex-vivo Expanded Activated NK Cell-lymphocytes (ANKL) and Doublet Chemotherapy in Patients With Advanced NSCLC as the 1st Line Treatment; Phase II

The object of this study is to identify the combined effect of ANKL and doublet chemotherapy in advanced NSCLC. The investigators design the combination of ANKL and approved chemotherapy as the 3rd and 4th courses in the patients who get stable response after x2 induction as the first line chemotherapy. ANKL (2x10*9) from peripheral blood 32ml is administered rapidly iv 12-36hr after each chemotherapeutic agents while peak effect of NK cell ligand modulation by chemotherapeutic agent is maintained. After 4th course, response evaluation is done by Response Evaluation Criteria in Solid Tumors (RECIST) and 40% or more partial response (PR, increased by 15% or more from historical control 25%) is the expected target and Simon's two stage design will be applied through the study (power 80%, a= 0.95, N1= 33, N= 68)

开始日期2015-02-01

申办/合作机构

The Catholic University of Korea

ISRCTN23727549 / CompletedN/AIIT

Comparison of benefits and safety between a CAPD technique with one icodextrin containing and two glucose containing dialysate a day and a CAPD technique with four exchanges of glucose-containing dialysates: a multicentre, prospective, randomized controlled trial

开始日期2008-04-14

申办/合作机构

The Catholic University of Korea

100 项与 The Catholic University of Korea 相关的临床结果

登录后查看更多信息

0 项与 The Catholic University of Korea 相关的专利（医药）

登录后查看更多信息

23,659

项与 The Catholic University of Korea 相关的文献（医药）

2025-02-01·Intensive and Critical Care Nursing

Impact of nursing policy on securing intensive care unit nurse staffing and in-hospital mortality

Article

作者: Kim, Seungju ; Han, Kyu-Tae

OBJECTIVEThis study aimed to evaluate changes in intensive care unit nurse staffing after the introduction of the government's nursing policy, and the relationship between ICU nurse staffing levels and in-hospital mortality.DESIGNA retrospective cohort study.SETTINGThis study used data from the Health Insurance Review and Assessment Service and included all patients admitted to adult ICUs at general and tertiary hospitals in Korea from 2016 to 2020.METHODSThe primary variables of interest in this study were the level and overall trend change in the outcome variables after introducing the nursing policy; the nurse-to-bed ratio in the ICUs was evaluated. The secondary variable of interest was the relationship between nurse staffing levels and in-hospital mortality. Interrupted time-series analysis and generalized estimating equation models were used to evaluate the primary and secondary variables of interest.RESULTSAfter the nursing policy was introduced, the nursing grades in the ICUs increased, especially in tertiary hospitals. The change at the time of the introduction of each policy was not statistically significant; however, after the introduction, the number of hospital beds per nurse decreased. In-hospital deaths of patients in ICUs increased as the number of beds per nurse increased (odds ratio [OR]: 1.17, 95 % confidence interval [CI]: 1.12-1.21) and decreased as the number of experienced nurses increased (OR: 0.97, 95 % CI: 0.96-0.98).CONCLUSIONSThe introduction of a nursing policy centered on financial support for medical institutions led to an increase in nurse hiring, leading to improved nursing grades. However, the results of introducing these policies differed by medical institution and region, and disparities between medical institutions appear to have widened further.IMPLICATIONS FOR CLINICAL PRACTICEExperienced nurses are important for better outcomes for patients admitted to ICUs, and continuous policy efforts are needed to secure and maintain sufficient nurses.

2025-01-01·Journal of Affective Disorders

Longitudinal analysis of anxiety and sleep disorders in the Korean population with disabilities, from 2006 to 2017: Incidence, prevalence, and association with disability type and severity

Article

作者: Kim, S.Y. ; Kim, Y Y ; Park, J H ; Kim, S Y ; Lee, H.-Y. ; Yeob, K E ; Lee, H-Y ; Yeob, K.E. ; Kim, Y.Y. ; Park, J.-H.

BACKGROUNDIndividuals with disabilities often face a higher risk of concurrent psychological problems, yet comprehensive assessments of the anxiety and sleep disorders in this population remain limited. This study examined longitudinal trends in the incidence and prevalence of anxiety and sleep disorders among people with disabilities and explored their associations with disability type and severity.METHODSUtilizing claim data from the National Health Insurance database and the National Disability Registry, which cover the entire Korean population, we estimated the age-standardized incidence and prevalence of anxiety and sleep disorders between 2006 and 2017. Logistic regression was used to analyze the associations between disability type and severity and these disorders.RESULTSThe unadjusted incidence and prevalence of anxiety and sleep disorders were consistently higher among individuals with disabilities during the study period. A significant gap in the prevalence of these disorders persisted between individuals with and without disabilities in both sexes, even after accounting for socioeconomic status and comorbidities. However, the incidence showed mixed results, with some categories of disabilities showing lower likelihood of developing the conditions compared to individuals without disabilities.CONCLUSIONSActions should also be taken to identify undiagnosed cases of anxiety and sleep disorders among individuals with disabilities. Moreover, individuals with disabilities who are diagnosed with these disorders should be more actively managed to avert the progression to the chronic stage.

2024-12-31·Emerging Microbes & Infections

Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus

Article

作者: Seo, Sang-Uk ; Sohn, Myung Hyun ; Moon, Dah-Hyun ; Hong, Su-Yeon ; Lee, Ah-Ra ; Seong, Baik-Lin ; Chung, Young-Uk ; Cho, Hyo Je ; Kim, Jae-Deog ; Kang, Tae Hyun ; Jang, Yo Han

Japanese encephalitis (JE), caused by the Japanese encephalitis virus (JEV), is a highly threatening disease with no specific treatment. Fortunately, the development of vaccines has enabled effective defense against JE. However, re-emerging genotype V (GV) JEV poses a challenge as current vaccines are genotype III (GIII)-based and provide suboptimal protection. Given the isolation of GV JEVs from Malaysia, China, and the Republic of Korea, there is a concern about the potential for a broader outbreak. Under the hypothesis that a GV-based vaccine is necessary for effective defense against GV JEV, we developed a pentameric recombinant antigen using cholera toxin B as a scaffold and mucosal adjuvant, which was conjugated with the E protein domain III of GV by genetic fusion. This GV-based vaccine antigen induced a more effective immune response in mice against GV JEV isolates compared to GIII-based antigen and efficiently protected animals from lethal challenges. Furthermore, a bivalent vaccine approach, inoculating simultaneously with GIII- and GV-based antigens, showed protective efficacy against both GIII and GV JEVs. This strategy presents a promising avenue for comprehensive protection in regions facing the threat of diverse JEV genotypes, including both prevalent GIII and GI as well as emerging GV strains.

100 项与 The Catholic University of Korea 相关的药物交易

登录后查看更多信息

100 项与 The Catholic University of Korea 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月20日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

7

6

临床前

其他

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

D-Pinitol ( APP x γ-secretase )	肾纤维化更多	临床前
peptide 4(CHA University) ( VEGFR3 )	急性髓性白血病更多	临床前
CAR33-KLRC1ko-NK ( CD33 )	鳞状细胞癌更多	临床前
LB-217 ( DDX53 )	非小细胞肺癌更多	临床前
LCB-03-110 ( CSK x DDR1 x JAK x STAT3 x VEGFR2 )	肿瘤更多	临床前